Search form
Search
contact us
Navigation
home
boards
job center
job ratings
cp wire
device news
trending now
trending in pharma/biotech
trending in device
pharmagather
advertise
Legal Help
login/register
You are here
Home
»
companies
» lymphoma
lymphoma
Cell Therapeutics: Empty Promises
Cell Therapeutics: Empty Promises
TheStreet.com
Cell Therapeutics
lymphoma
pixantrone
Flag link:
Seattle Genetics, Takeda Drug Shrinks Lymphoma Patients' Tumors in Study
Seattle Genetics, Takeda Drug Shrinks Lymphoma Patients' Tumors in Study
Bloomberg
Seattle Genetics
Takeda
lymphoma
Hodgkin's lymphoma
Flag link:
Allos Presents Early-stage Data
Allos Presents Early-stage Data
Yahoo/Zacks.com
Folotyn
Allos
lymphoma
Flag link:
Rituxan, Revlimid win in maintenance trials
Rituxan, Revlimid win in maintenance trials
Fierce Pharma
Rituxan
Revlimid
Genentech
clinical trials
lymphoma
Roche
Biogen Idec
Flag link:
Cell Therapeutics' FDA Panel: Live Blog
Cell Therapeutics' FDA Panel: Live Blog
TheStreet.com
FDA
Cell Therapeutics
pixantrone
lymphoma
Flag link:
Data Monitoring Committee Recommends Continuation Of Phase III Study Of StemEx(R), A Cord Blood Stem Cell Product, For Leukemia And Lymphoma
Data Monitoring Committee Recommends Continuation Of Phase III Study Of StemEx(R), A Cord Blood Stem Cell Product, For Leukemia And Lymphoma
Medical News Today
stem cells
leukemia
lymphoma
StemEx
Flag link:
Cell Therapeutics’ Last Hope for Survival, Dashed
Cell Therapeutics’ Last Hope for Survival, Dashed
Minyanville
Cell Therapeutics
pixantrone
lymphoma
Flag link:
FDA Raises Concerns About Cell Therapeutics' Cancer Drug
FDA Raises Concerns About Cell Therapeutics' Cancer Drug
TheStreet.com
Cell Therapeutics
FDA
pixantrone
lymphoma
Flag link:
Cell Therapeutics Has Strange Timing
Cell Therapeutics Has Strange Timing
TheStreet.com
Cell Therapeutics
pixantrone
lymphoma
Flag link:
Cell Therapeutics Gets FDA Panel for Lymphoma Drug
Cell Therapeutics Gets FDA Panel for Lymphoma Drug
TheStreet.com
FDA
Cell Therapeutics
lymphoma
pixantrone
Flag link:
Introducing the $30,000 Per Month Cancer Drug
Introducing the $30,000 Per Month Cancer Drug
WSJ Online
cancer
Folotyn
lymphoma
Allos
Flag link:
Patent issued for Allos Therapeutics' cancer drug Folotyn
Patent issued for Allos Therapeutics' cancer drug Folotyn
Bizjournals.com
Allos
Folotyn
patents
lymphoma
Flag link:
Seattle Genetics Halts Lymphoma Drug Study
Seattle Genetics Halts Lymphoma Drug Study
TheStreet.com
Seattle Genetics
lymphoma
drug studies
dacetuzumab
non-Hodgkin's lymphoma
Flag link:
FDA Approves Allos Lymphoma Drug
FDA Approves Allos Lymphoma Drug
TheStreet.com
FDA
lymphoma
Allos
Folotyn
Flag link:
Rituxan tests positive in Phase III trial
Rituxan tests positive in Phase III trial
Fierce Pharma
Rituxan
Genentech
lymphoma
Flag link:
Cell Therapeutics posts follow-up cancer drug data
Cell Therapeutics posts follow-up cancer drug data
Yahoo/AP
Cell Therapeutics
lymphoma
pixantrone
Flag link:
Genmab slumps as Glaxo-partnered drug hits setback
Genmab slumps as Glaxo-partnered drug hits setback
Reuters
GSK
Genmab
Arzerra
lymphoma
Flag link:
Allos Therapeutics says FDA advisory committee will review lymphoma drug in September
Allos Therapeutics says FDA advisory committee will review lymphoma drug in September
Yahoo/AP
FDA
Allos
lymphoma
Pralatrexate
Flag link:
Pages
« first
‹ previous
1
2
3